Value Sense
SMMT
Summit Therapeutics Inc. (SMMT)
Last Price$19.1(7.5%)
Market Cap$14.6B
LTM Return on Assets (ROA)
(47.2%)
5Y avg
(91.0%)
Biotechnology industry median
(44.6%)
Stock quality & Intrinsic value
6/10
(1.0%) overvalued
SMMT
is (97.4%) overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Summit Therapeutics Inc. Return on Assets (ROA)

Annual
Quarterly
LTM
Industry median
Company stand-alone
SMMT
Healthcare
Crunching data... Almost there!
Jan'06Jan'07Jan'08Jan'09Jan'10Jan'11Jan'12Jan'13Jan'14Jan'15Jan'16Jan'17Jan'18Jan'19Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Return on Assets (ROA)
(12.2%)
(23.8%)
(40.4%)
(78.4%)
(35.3%)
(71.0%)
(66.5%)
(110.7%)
(123.8%)
(95.0%)
(88.4%)
(77.7%)
(25.0%)
8.5%
(31.1%)
(59.2%)
(82.1%)
(20.3%)
(141.8%)
(69.3%)
SMMT
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for SMMT and see if it's the right time to invest.
Dive in

Summit Therapeutics Inc. (SMMT) Return on Assets (ROA) comparison analysis

General

LTM Return on Assets (ROA)

OTHER METRICS

Company name

Revenue growth

EPS growth

Net Income margin

Summit Therapeutics Inc. logo
Summit Therapeutics Inc.SMMT
(47.2%)
N/A
(68.7%)
N/A
Median Peer Set
(0.7%)
18.9%
(41.2%)
12.6%
Novo Nordisk A/S logo
Novo Nordisk A/SNVO
23.4%
24.9%
142.8%
34.8%
United Therapeutics Corporation logo
United Therapeutics CorporationUTHR
16.5%
23.6%
25.7%
41.5%
Regeneron Pharmaceuticals, Inc. logo
Regeneron Pharmaceuticals, Inc.REGN
11.7%
8.3%
10.4%
31.1%
Incyte Corporation logo
Incyte CorporationINCY
0.6%
14.8%
(94.0%)
0.8%
Royalty Pharma plc logo
Royalty Pharma plcRPRX
0.0%
(3.8%)
(43.7%)
37.9%
BioNTech SE logo
BioNTech SEBNTX
(1.4%)
(77.4%)
(89.7%)
24.4%
Vertex Pharmaceuticals Incorporated logo
Vertex Pharmaceuticals IncorporatedVRTX
(2.4%)
11.7%
N/A
(4.9%)
argenx SE logo
argenx SEARGX
(4.3%)
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc. logo
Alnylam Pharmaceuticals, Inc.ALNY
(6.6%)
23.0%
(38.6%)
(12.4%)
BeiGene, Ltd. logo
BeiGene, Ltd.BGNE
(14.9%)
73.7%
(56.5%)
(35.9%)

SMMT key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Jan'06Jan'07Jan'08Jan'09Jan'10Jan'11Jan'12Jan'13Jan'14Jan'15Jan'16Jan'17Jan'18Jan'19Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Revenue
% growth
1.7
338.9%
3.8
119.8%
12.1
219.9%
0.5
(96.0%)
0.5
(1.1%)
1.9
290.6%
4.4
138.3%
4.6
2.5%
3.6
(21.8%)
3.7
4.3%
0.0
(100.0%)
3.9
0.0%
46.8
1,114.8%
74.9
59.9%
0.8
(98.9%)
0.9
6.6%
1.8
110.3%
0.7
(61.1%)
0.0
(100.0%)
0.0
0.0%
Cost of Goods Sold (COGS)0.81.15.00.00.00.01.60.00.00.00.00.00.10.00.20.00.02.52.115.0
Gross Profit
% margin
1.0
56.1%
2.7
70.6%
7.0
58.3%
0.5
97.8%
0.5
100.0%
1.9
100.0%
2.8
63.7%
4.6
100.0%
3.6
100.0%
3.7
100.0%
0.0
0.0%
3.9
100.0%
46.7
99.7%
74.8
100.0%
0.6
75.4%
0.9
100.0%
1.8
100.0%
(1.8)
(257.0%)
(2.1)
0.0%
(15.0)
0.0%
Operating Expenses6.818.653.927.915.08.611.913.520.931.644.845.470.463.353.653.288.064.387.7211.3
Research & Development Expenses (R&D)3.310.830.713.35.85.77.79.117.025.636.431.753.468.241.753.385.452.059.5150.8
Selling, General & Administrative Expenses (SG&A)3.23.514.69.16.64.13.74.45.111.111.313.822.121.511.919.223.626.728.260.5
Operating Income
% margin
(5.8)
(338.9%)
(16.0)
(423.8%)
(46.9)
(388.4%)
(34.7)
(7,198.9%)
(14.5)
(3,047.6%)
(14.5)
(777.1%)
(7.6)
(170.1%)
(11.5)
(252.3%)
(17.4)
(487.9%)
(31.3)
(844.4%)
(43.7)
0.0%
(41.6)
(1,078.7%)
(23.7)
(50.7%)
16.4
21.9%
(54.6)
(6,766.4%)
(53.2)
(6,185.2%)
(86.2)
(4,764.3%)
(72.1)
(10,235.6%)
(89.7)
0.0%
0.3
0.0%
Interest Income1.93.23.10.80.00.00.00.00.00.00.00.05.74.90.00.00.21.510.40.0
Interest Expense0.00.00.20.20.20.00.00.00.00.70.01.42.10.70.00.30.34.416.5(8.7)
Pre-tax Income(3.9)(12.8)(43.9)(34.2)(14.7)(14.4)(7.5)(11.5)(17.3)(31.2)(43.7)(43.0)(20.1)8.8(36.3)(52.9)(88.6)(78.8)(615.9)(221.3)
Income Tax
% effective tax rate
(0.5)
12.8%
(1.8)
13.9%
(3.6)
8.3%
(4.6)
13.3%
(0.9)
6.4%
(3.0)
20.7%
(0.8)
10.1%
(0.9)
7.5%
(1.6)
9.1%
(3.2)
10.2%
(6.6)
15.2%
(7.3)
16.9%
(6.9)
34.5%
(4.3)
(49.6%)
(5.8)
15.9%
(0.2)
0.4%
(2.5)
2.8%
(4.4)
5.6%
(0.9)
0.2%
0.0
0.0%
Net Income
% margin
(3.4)
(199.7%)
(11.0)
(292.1%)
(40.3)
(334.1%)
(58.4)
(12,109.8%)
(13.7)
(2,867.2%)
(11.4)
(614.7%)
(6.8)
(152.6%)
(10.6)
(232.9%)
(15.8)
(443.1%)
(28.0)
(754.9%)
(37.0)
0.0%
(35.7)
(927.6%)
(13.1)
(28.1%)
13.1
17.5%
(30.5)
(3,779.1%)
(52.7)
(6,127.6%)
(86.1)
(4,762.1%)
(74.4)
(10,561.1%)
(614.9)
0.0%
(221.3)
0.0%
EPS(0.11)(0.30)(0.84)(1.09)(0.21)(0.07)(0.04)(0.67)(3.26)(0.70)(0.62)(0.58)(0.21)0.15(0.19)(0.76)(0.93)(0.38)(0.99)(0.31)
Diluted EPS(0.11)(0.30)(0.84)(1.09)(0.21)(0.07)(0.04)(0.67)(3.26)(0.70)(0.62)(0.58)(0.20)0.15(0.19)(0.76)(0.93)(0.38)(0.99)(0.31)
EBITDA
% margin
(5.4)
(313.6%)
(11.4)
(302.4%)
(37.2)
(308.4%)
(29.0)
(6,010.3%)
(8.5)
(1,790.5%)
(13.3)
(716.0%)
(7.1)
(159.0%)
(8.7)
(191.3%)
(17.3)
(486.0%)
(20.0)
(537.9%)
(30.9)
0.0%
(41.5)
(1,075.8%)
(41.9)
(89.5%)
15.5
20.7%
(21.4)
(2,657.4%)
(37.1)
(4,317.9%)
(62.7)
(3,468.0%)
(52.6)
(7,472.8%)
1.0
0.0%
0.3
0.0%

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Summit Therapeutics Inc.'s Return on Assets (ROA)?

As of today, Microsoft Corp's last 12-month Return on Assets (ROA) is (47.2%), based on the financial report for Dec 31, 2024 (Q4’2024). The average annual Return on Assets (ROA) for Summit Therapeutics Inc. have been (104.8%) over the past three years, and (95.6%) over the past five years.

2) Is Summit Therapeutics Inc.'s Return on Assets (ROA) Good?

As of today, Summit Therapeutics Inc.'s Return on Assets (ROA) is (47.2%), which is lower than industry median of (44.6%). It indicates that Summit Therapeutics Inc.'s Return on Assets (ROA) is Bad.

3) How does Summit Therapeutics Inc.'s Return on Assets (ROA) compare to its peers?

As of today, Summit Therapeutics Inc.'s Return on Assets (ROA) is (47.2%), which is lower than peer median of (0.7%). The list of peers includes NVO, UTHR, REGN, INCY, RPRX, BNTX, VRTX, ARGX, ALNY, BGNE.